BIOTECanada welcomes the launch of CanReview, a pan-Canadian initiative supported by the Accelerating Clinical Trials (ACT) Consortium, as a major step forward for Canada’s life sciences ecosystem.
By replacing multiple provincial ethics reviews with a single, national process, CanReview is breaking down interprovincial barriers, speeding up clinical trial start-up, and making Canada more competitive on the global stage. This collaborative framework builds on Canada’s world-leading reputation for science at a time when geopolitical uncertainty demands decisive, coordinated action.
For Canada to remain a top location for clinical trials, the healthcare system must deliver:
- Faster, smoother clinical trial start-ups;
- A clear competitive advantage in attracting clinical trials;
- Broader access for underserved, rural, and remote communities; and
- Equitable access for patients to participate
- CanReview enables Canada to address these needs.
The biotech ecosystem is driven by discovering and delivering innovative solutions that advance access to care, and improve the health of Canadians. This initiative will contribute to creating a stronger environment for emerging Canadian biotech companies and their products to thrive at home.
For more information, visit: https://canreview.ca/